Cardiogenol C

A cell-permeable pyrimidine compound that potently induces the differentiation of ESCs (embryonic stem cells) into cardiomyocytes (EC₅₀ = 100 nM) without significant cytotoxic effect even at concentrations as high as 25 µM. The induction of cardiomyogenesis by Cardiogenol C is much more efficient than that achieved by EBs (embryoid bodies) formation and DMSO treatment.

A cell-permeable pyrimidine compound that potently induces the differentiation of embryonic stem cells (ESCs) into cardiomyocytes (EC₅₀ = 100 nM). Does not exhibit cytotoxic effects even at concentrations as high as 25 µM. The induction of cardiomyogenesis by Cardiogenol C is reported to be more efficient than that achieved by embryoid bodies (EBs) and DMSO treatment.

Cell permeable: yes

EC50 = 100 nM inducing the differentiation of ESCs (embryonic stem cells) into cardiomyocytes

Primary Target
Differentiation of ESCs (embryonic stem cells) into cardiomyocytes

Product does not compete with ATP.

Reversible: no

Packaged under inert gas

Toxicity: Carcinogenic / Teratogenic (D)

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Wu, X., et al. 2004. J. Am. Chem. Soc.126, 1590.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany